Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
24.34 USD | +1.42% |
|
-4.21% | +208.49% |
May. 31 | Jasper Therapeutics, Inc. to Present Data on Briquilimab in Mast Cell Driven Diseases at the EAACI Congress 2024 | CI |
May. 20 | Transcript : Jasper Therapeutics, Inc. - Special Call |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+208.49% | 362M | |
+51.54% | 781B | |
-7.20% | 350B | |
+18.67% | 330B | |
+7.48% | 293B | |
+16.91% | 248B | |
+0.53% | 221B | |
+11.06% | 217B | |
+3.64% | 162B | |
-3.96% | 157B |
- Stock Market
- Equities
- JSPR Stock
- News Jasper Therapeutics, Inc.
- Jasper Therapeutics : BMO Initiates Jasper Therapeutics at Outperform Rating With $19 Price Target